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Mitochondrial carrierThe structure/function relationships of charged residues of the human mitochondrial carnitine/acylcarnitine
carrier, which are conserved in the carnitine/acylcarnitine carrier subfamily and exposed to the water-ﬁlled
cavity of carnitine/acylcarnitine carrier in the c-state, have been investigated by site-directed mutagenesis.
The mutants were expressed in Escherichia coli, puriﬁed and reconstituted in liposomes, and their transport
activity was measured as 3H-carnitine/carnitine antiport. The mutants K35A, E132A, D179A and R275A were
nearly inactive with transport activities between 5 and 10% of the wild-type carnitine/acylcarnitine carrier.
R178A, K234A and D231A showed transport function of about 15% of the wild-type carnitine/acylcarnitine
carrier. The substitutions of the other residues with alanine had little or no effect on the carnitine/
acylcarnitine carrier activity. Marked changes in the kinetic parameters with three-fold higher Km and lower
Vmax values with respect to the wild-type carnitine/acylcarnitine carrier were found when replacing Lys-35,
Glu-132, Asp-179 and Arg-275 with alanine. Double mutants exhibited transport activities and kinetic
parameters reﬂecting those of the single mutants; however, lack of D179A activity was partially rescued by
the additional mutation R178A. The results provide evidence that Arg-275, Asp-179 and Arg-178, which
protrude into the carrier's internal cavity at about the midpoint of the membrane, are the critical binding
sites for carnitine. Furthermore, Lys-35 and Glu-132, which are very probably involved in the salt-bridge
network located at the bottom of the cavity, play a major role in opening and closing the matrix gate.aleimide; Pipes, 1,4-piperazi-
l sulfate polyacrylamide gel
T, wild-type
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The mitochondrial carnitine/acylcarnitine carrier (CAC) belongs to a
large family of transport proteins called the mitochondrial carrier family
[1, and refs. 2 and 3 for reviews]. Members of this family have common
structural features; they are made up of three tandemly repeated
homologous domains about 100 amino acids in length, and each repeat
contains two hydrophobic segments (spanning the membrane as α-
helices) and a characteristic sequence motif PX[D/E]XX[K/R]. CACs of
several species have been identiﬁed by transport assays and/or by their
high similarity to orthologs in other organisms [4–9]. Multiple sequencealignment of the CAC proteins revealed that they constitute a subfamily
characterized by the RXXPANAAXF motif [9] and by speciﬁc triplets of
amino acids [3,10]. This subfamily of mitochondrial carriers catalyzes
carnitine/acylcarnitine and carnitine/carnitine antiport efﬁciently and, in
the absence of counter-substrate, a slower carnitine uniport [11,12]. Both
the homologous carnitine/carnitine exchange and the heterologous
carnitine/acylcarnitine exchange occur via a ping-pong transport
mechanism, implying the existence of two opposite conformations in
which the substrate-binding site is alternately exposed towards the
cytosol (c-state) or towards the matrix (m-state) [13 and refs. therein].
Physiologically, CAC is important in mammals as it allows the net import
of fatty acyl units into mitochondria by catalyzing an exchange between
extramitochondrial acylcarnitine and internal free carnitine. This trans-
port reaction is essential for fatty acid β-oxidation, as conﬁrmed by the
identiﬁcation of a disease known as carnitine carrier deﬁciency caused by
mutations in theCACgene [5 and14 for a review]. Anothermemberof the
mitochondrial carrier family (accession no. NP001034444) was reported
to accept long chain acylcarnitines [15]. However, this protein was later
identiﬁed as an ornithine transporter [16].
The signiﬁcant sequence conservation in the mitochondrial carrier
family suggests that the main structural fold is similar for all carriers
[17]. Until now, the 3D structure of only one member of the
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its powerful inhibitor carboxyatractyloside, has been determined
[18]. This structure consists of six transmembrane α-helices (H1–
H6) and three hydrophilic short α-helices (h12, h34 and h56)
parallel to the membrane plane. The H1–H6 bundle delimits a
funnel-shaped cavity opened towards the cytosol and closed on the
matrix side by a salt-bridge network (matrix gate) formed by the
charged residues of the signature motifs. The crystal structure of
the ADP/ATP carrier, which roughly corresponds to the c-state of
mitochondrial carriers, has stimulated further research in the ﬁeld
of CAC. Indeed, the studies on CAC structure-function relationships
already undertaken [19,20] have continued by combining homol-
ogy modeling with site-directed mutagenesis and speciﬁc chemical
labeling. It was found that Cys-136, CAC's major target of SH-
blocking reagents, protrudes into the internal carrier cavity, and
that the loop between H3 and H4 containing Cys-136 and Cys-155
undergoes conformational changes during the catalytic transport
cycle [21,22]. Furthermore, it was found that His-29, which is
conserved in all the members of the CAC subfamily and protrudes
into the carrier cavity just above the matrix gate, participates in
the substrate translocation mechanism [23]. Evidence was providedFig. 1. Alignment of proteins of the mitochondrial carnitine carrier subfamily. CAC proteins
NP014743 from S. cerevisiae, AJ011563 from A. nidulans, NP065266 from M. musculus, XP00
from D. melanogaster, and NP001065471 from O. sativa) were aligned using the Clustal W
substitutions are indicated by dots or colons, respectively. The Lys, Arg, Glu and Asp residues
of the human CAC (see Fig. 4), are highlighted in gray.that His-29 interacts via an H-bond with the alcoholic β-OH of
carnitine or with the esteriﬁed β-O− of acylcarnitine, presumably
playing a role in positioning the substrate prior to the opening of
the matrix gate. In the present paper, the structure/function
relationships of the Lys, Arg, Asp and Glu residues, which are
exposed to the central cavity and conserved in the CAC subfamily,
have been investigated. The experimental data shed light on the
molecular mechanism of substrate transport and, in particular, on
the binding of carnitine to CAC and opening/closing of the matrix
gate.2. Materials and methods
2.1. Materials
Sephadexes G-50, G-75 and G-200 were purchased from Phar-
macia, l-[methyl-3H]carnitine from Amersham, egg-yolk phospholi-
pids (l-α-phosphatidylcholine from fresh turkey egg yolk), Pipes,
Triton X-100, cardiolipin, l-carnitine and N-dodecanoylsarcosine
(sarkosyl) from Sigma. All other reagents were of analytical grade.(NP446417 from R. norvegicus, NP000378 from H. sapiens, NP568670 from A. thaliana,
1253588 from B. taurus, NP957153 from D. rerio, NP501223 from C. elegans, NP477221
software. Identities are indicated by asterisks and conservative or highly conservative
, which are conserved and face the water-ﬁlled cavity according to the homology model
Fig. 2. WT and mutant CAC proteins incorporated into liposomes. Equal amounts of
proteoliposomes reconstituted with WT and the indicated mutants of CAC were passed
through Sephadex G-200 columns and 200 μl of the pass-throughwere ultracentrifuged
at 110,000×g. The sediment was solubilized with 2% SDS, precipitated with acetone and
then applied to the gel. After electrophoresis the gel was stained by silver-staining. The
WT CAC was applied in the ﬁrst line of each gel for comparison with single substitution
mutants (A and B) and double substitution mutants (C).
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CAC proteins
The previously constructed pMW7-WT human CAC recombinant
plasmid [9] was used to introduce the mutations in the CAC protein.
The amino acid replacements were performed with complementary
mutagenic primers using the overlap extension method [24] and the
High Fidelity PCR System (Roche). The PCR products were puriﬁed
using the Gene Clean Kit (La Jolla), digested with NdeI and HindIII
(restriction sites added at the 5′ end of forward and reverse primers,
respectively) and ligated into the pMW7 expression vector. All
mutations were veriﬁed by DNA sequencing and, except for the
desired base changes, all the sequences were identical to that of
human CAC cDNA. The resulting plasmids were transformed into
Escherichia coli C0214. Bacterial overexpression, isolation of inclusion
bodies, solubilization and puriﬁcation of WT and mutant CAC proteins
were performed as previously described [4].
2.3. Reconstitution of wild-type and mutant CAC proteins in liposomes
The recombinant proteins were reconstituted into liposomes as
described previously [4,25]. The concentration of intraliposomal
carnitine was 15 or 50 mM. The external substrate was removed
from proteoliposomes on Sephadex G-75 columns.
2.4. Transport measurements
Transport was measured as [3H]carnitine/carnitine homoex-
change. This is a suitable mode for measuring the activity of CAC in
proteoliposomes [4,9,13,19,21,23], though it has no physiological
relevance. Transport at 25 °C was started by adding 0.1 mM [3H]
carnitine to proteoliposomes and terminated by the addition of
1.5 mMNEM [4,25]. In controls, the inhibitor was added together with
the labeled substrate, according to the inhibitor stop method [25].
Finally, the external substrate was removed by chromatography on
Sephadex G-50 columns and radioactivity in the liposomes was
measured [25]. The experimental values were corrected by subtract-
ing control values. Transport activities were calculated by taking into
account the efﬁciency of reconstitution (i.e. the share of successfully
incorporated protein).
2.5. Other methods
SDS-PAGE was performed according to Laemmli [26] as previously
described [4]. The amount of recombinant protein was estimated on
Coomassie blue-stained SDS-PAGE gels by the Bio-Rad GS-700
Imaging Densitometer equipped with the software Bio-Rad Multi-
Analyst, using bovine serum albumin as standard. The extent of
incorporation of the recombinant protein in liposomes was deter-
mined as described in Phelps et al. [27], with the modiﬁcations
reported in ref. [20]. The homology model of the human CAC was
constructed using the structure of the bovine ADP/ATP carrier [18] as
template and the computer application Swiss PDB Viewer [28] as
previously described for the rat CAC [21].
3. Results
The role of the charged amino acid residues, which are conserved
in the CAC subfamily (Fig. 1) and face the water-ﬁlled carrier cavity
based on the CAC homology model (Fig. 5), has been investigated in
the Homo sapiens recombinant protein by site-directed mutagenesis.
The mutant proteins, over-expressed in E. coli and reconstituted in
liposomes, were compared with the WT protein in terms of transport
function and kinetic parameters of transport. The amount of single
(Fig. 2 A and B) and double (Fig. 2C) mutant CAC proteins
incorporated into liposomes was similar to that of the WT CAC. InFig. 3 the transport activities of WT and mutants have been depicted
as a function of time. Among the mutants of the positively charged
amino acids Arg and Lys (Fig. 3A), K97A, K135A and K194A showed
transport functions comparable to WT; at 30 min the transport
activities of K97A and K135Awere 88% of that ofWT and the transport
activity of K194A was 82% as compared to WT. R178A and K234A
exhibited very low transport activities (about 15% of that of WT at
30 min), whereas K35A was nearly inactive (residual activity b7% of
WT) as the previously described R275A mutant [9]. Among the
mutants of negatively charged residues (Fig. 3B), E191A and E288A
showed transport activities comparable to or somewhat lower than
that of WT; at 30 min they were 103 and 70% of that of WT,
respectively. The mutants D32A and D231A displayed much lower
transport activities than that of WT; i.e., 36 and 14% at 30 min,
respectively. E132A and D179A were nearly inactive with transport
activities lower than 6% of WT.
To gain further insight into the role of the individual residues
whose substitution with Ala led to nearly inactive proteins, conser-
vative mutants were constructed. In Fig. 3C K35R, E132D, R178K and
D179E showed transport activities of 37, 87, 38 and 49 %, respectively,
compared to WT at 30 min. The amino acids Asp-32, Lys-35, Glu-132,
Lys-135, Asp-231 and Lys-234 were also mutated with Cys, a residue
which has been previously used in mutagenesis studies of other
mitochondrial transporters [17,29–35]. As shown in Fig. 3C, the
mutants K135C and K234C in contrast to the Ala mutants were nearly
inactive, whereas the mutant D32C exhibited a transport activity (12%
of WT at 30 min) lower than that of D32A shown in Fig. 3B. In
addition, K35C, E132C and D231C were inactive (not shown). These
results indicated that the electric charges of Lys-35, Glu-132, Arg-178
and Asp-179 are essential for transport and that the Cys residue is
more deleterious to function than the Ala residue.
In another set of experiments, double mutants were constructed
and assayed for transport activity in proteoliposomes. Fig. 4A shows
the results of substitutions of amino acid pairs among the six charged
residues of the carrier motifs (Fig. 6). Two types of double
substitutions were performed; the ﬁrst concerns residues located in
different transmembrane segments (inter-helix) that are predicted to
form the salt-bridge network closing the internal CAC cavity on the
matrix side (D32A/K135A; K35A/D231A; E132A/K234A), and the
second proximal residues located on the same transmembrane
segment (intra-helix, D32A/K35A; E132A/K135A; D231A/K234A).
Among the inter-helix double mutants (Fig. 4A), D32A/K135A was
partially active with 41% of transport activity with respect to WT at
Fig. 3. Time course of [3H]-carnitine uptake in liposomes reconstituted with
recombinant WT and single mutant CAC proteins. Transport was started by the
addition of 0.1 mM [3H]-carnitine to proteoliposomes containing 15 mM carnitine and
terminated at the indicated times. In each panel the data relative to theWT CAC (O) are
shown together with those relative to the indicated CAC mutants. The data represent
means±SD of at least three independent experiments.
Fig. 4. Time course of [3H]-carnitine uptake in liposomes reconstituted with
recombinant WT and double mutant CAC. Transport was started by the addition of
0.1 mM [3H]-carnitine to proteoliposomes containing 15 mM carnitine and terminat-
ed at the indicated times. In each panel the data relative to the WT CAC (O) are
shown together with those relative to the indicated CAC mutants. The data represent
means±SD of at least three independent experiments.
Table 1
Kinetic constants of reconstituted CAC WT and single-replacement mutants.
Km Vmax Vmax/Km
Protein (mM) (μmol/min/mg) (ml/min/mg)
WT 0.86±0.19 1.1±0.30 1.3
D32A 0.68±0.25 0.36±0.13 0.53
K35A 2.8±0.39 0.21±0.09 0.08
K35R 0.95±0.07 0.68±0.29 0.72
K97A 1.5±0.14 1.2±0.42 0.80
E132A 3.0±0.73 0.10±0.06 0.03
E132D 0.86±0.10 1.1±0.26 1.3
K135A 2.0±0.40 1.2±0.60 0.60
R178A 2.0±0.35 0.24±0.07 0.12
R178K 0.81±0.23 0.42±0.08 0.52
D179A n.m. n.m.
D179E 3.4±0.47 0.90±0.52 0.26
E191A 0.60±0.15 0.56±0.22 0.93
K194A 0.78±0.16 0.90±028 1.2
D231A 0.59±0.20 0.19±0.07 0.32
K234A 1.8±0.51 0.44±0.12 0.24
R275A(a) n.m. n.m.
R275K(a) 2.3±0.50 0.50±0.19 0.21
E288A 0.62±0.09 0.31±0.07 0.50
The Km and Vmax values were calculated from double-reciprocal plots of the rates of
carnitine/carnitine antiport under variation of the external substrate concentration.
Transport was started by adding 0.12–2.0 mM [3H]carnitine to proteoliposomes
reconstituted with CAC WT or one of the indicated mutants and containing 50 mM
carnitine. The reaction time was 4 min. The data represent the means±SD of four
different experiments; n.m., not measurable; (a) data from ref. [9].
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were almost inactive with less than 7% transport activity compared to
WT. The intra-helix double mutant D231A/K234A exhibited a
transport activity of 15% compared to WT at 30 min, whereas the
mutants D32A/K35A and E132A/K135A were nearly inactive with
less than 7% of the function with respect to WT. Further combinations
of double substitutions were performed on the three residues Arg-
178, Asp-179 and Arg-275 found to be important for transport
function (see Fig. 3 and ref. [9] for R275A activity). R178A/R275A and
D179A/R275A exhibited transport activities lower than 5% of WT
(Fig. 4B). In contrast, the R178A/D179A double mutant was much
more active (31% of WT) than each of the single mutants R178A and
D179A shown in Fig. 3. The double mutant R178D/D179R, in which
the two adjacent amino acids were exchanged, was virtually as
inactive as the double mutants R178A/R275A and D179A/R275A
(Fig. 4B).
The effect of mutagenesis on the kinetic parameters of CAC is
reported in Tables 1 and 2. In these experiments, the concentration of
intraliposomal carnitine was increased from 15 to 50 mM to enhance
the accumulation of the radioactive substrate inside the proteolipo-
somes, as was performed previously for the citrate carrier [32]. This
increase in internal carnitine concentration did not signiﬁcantly
inﬂuence the Km of carnitine for the WT protein (not shown). Thelargest variations in Km value (Table 2) were observed with the
mutants K35A, E132A and D179E, which exhibited values more than
three-fold greater than that of WT. Km values higher than that of WT,
from 1.5 to 2.3 mM, were observed for the mutants K97A, K135A,
R178A, K234A, and R275K. By contrast, the mutants D32A, K35R,
E132D, R178K, E191A, K194A, D231A and E288A showed Km values
similar to or not much lower than that of WT. Except for K97A, E132D,
K135A, D179E and K194A, the other mutants showed signiﬁcant
decreases in Vmax as compared to WT. The relatively high SD of the
Table 2
Kinetic constants of reconstituted CAC double-replacement mutants.
Protein Km Vmax Vmax/Km
(mM) (μmol/min/mg) (ml/min/mg)
D32A/K35A 2.7±0.80 0.10±0.04 0.04
E132A/K135A n.m. n.m.
D231A/K234A 1.7±0.20 0.23±0.18 0.14
D32A/K135A 2.5±1.0 0.40±0.24 0.16
K35A/D231A 2.9±0.77 0.10±0.04 0.03
E132A/K234A n.m. n.m.
R178A/D179A 3.7±0.64 0.36±0.16 0.10
R178D/D179R n.m. n.m.
D179A/R275A n.m. n.m.
The Km and Vmax values were calculated from double-reciprocal plots of the rates of
carnitine/carnitine antiport under variation of the external substrate concentration.
Transport was started by adding 0.12–2.0 mM [3H]carnitine to proteoliposomes
reconstituted with the indicated mutant and containing 50 mM carnitine. The
reaction time was 4 min. The data represent the means±SD of four different
experiments; n.m., not measurable.
Fig. 5. Structural model of CAC. Ribbon diagrams viewing the carrier from the lateral
side. Dark gray (negatively charged residues) and white (positively charged residues)
surfaces highlight the residues Asp-32, Lys-35, Glu-132, Lys-135, Asp-231 and Lys-
234; medium gray surfaces highlight the residues Arg-178, Asp-179 and Arg-275;
and light gray surfaces highlight the residues Lys-97, Glu-191, Lys-194 and Glu-288.
The homology model has been represented using the molecular visualization
program VMD.
Fig. 6. View of the CAC residues involved in the matrix salt-bridge network (matrix
gate). The residues are depicted in a ball and stick representation with side-chains in
dark gray and backbone in white. The salt bridges are highlighted by dotted lines.
Segments of the oddα-helices H1, H3 and H5 containing the indicated charged residues
are represented. The homology model has been represented using the molecular
visualization program VMD.
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protein within the different preparations. Most mutants displayed a
decreased catalytic efﬁciency (Vmax/Km) compared to WT, with the
exception of E132D and K194A. Furthermore, under the experimental
conditions employed (i.e., internal carnitine concentration of 50 mM)
the transport activities of D179A and R275A were still unmeasurable.
Concerning the kinetic parameters of the CAC double mutants
(Table 2), D32A/K35A, D32A/K135A, K35A/D231A and D231A/
K234A exhibited Km values similar to those of the single mutants
with higher Km reported in Table 2. On the other hand, with the
exception of R178A/D179A, the Vmax values of the double mutants
were comparable to those of the single mutants with lower Vmax
reported in Table 2. Surprisingly, in the case of R178A/D179A, a Vmax
of 0.36 µmol/min/mg protein was measured, although one of the
single mutants (D179A) was completely inactive. In addition, the
kinetic parameters of E132A/K135A, E132A/K234A, R178D/D179R
and D179A/R275A could not be determined, since the transport
activities of these proteins were unmeasurable even in the presence of
50 mM internal carnitine.
4. Discussion
The basic conformation of mitochondrial carriers in the c-state is a
six α-helical bundle which delimits a water-ﬁlled cavity closed
towards the matrix and opened towards the cytosol (see ref. [18] and
Fig. 5). The substrate must enter the cavity and bind to speciﬁc
residues to trigger the conformational changes required for opening
the matrix gate and for substrate translocation. Carnitine has one
positive and one negative charge; thus, it is expected to interact with
both negatively and positively charged residues. Thus, we investigat-
ed the role of CAC charged residues that line the central water-ﬁlled
cavity of the transport protein and are conserved in the CAC subfamily
of mitochondrial carriers. These residues can be divided into three
groups: (1) Asp-32, Lys-35, Glu-132, Lys-135, Asp-231 and Lys-234,
which are located at the bottom of the cavity at the C-terminus of the
odd-numbered transmembrane α-helices (Fig. 5, dark gray and white
residues) and are predicted, on the basis of the structural similarity
with the ADP/ATP carrier, to form an inter-helix salt-bridge network
that closes the transporter in the c-state on the matrix side [18,36]. In
CAC the three ion pairs would result from the interactions between
Asp-32 and Lys-135, Glu-132 and Lys-234, and Asp-231 and Lys-35
(Fig. 6). (2) Arg-178, Asp-179 and Arg-275, which are located in the
cavity at the midpoint of the membrane (Fig. 5, medium gray
residues) and concern positions that have been proposed to constitute
the common substrate binding site of mitochondrial carriers [37]. (3)
Lys-97, Glu-191, Lys-194 and Glu-288, which are located at the C-
terminus of the even-numbered transmembrane α-helices (Fig. 5,light gray residues) and have been proposed to form a salt-bridge
network on the cytoplasmic side when the cavity is opened on the
matrix side (m-state) [10]. In CAC the other two residues of the
proposed network are the uncharged Gly-94 and Met-291.
The single replacements of Glu-132, Lys-234, Lys-35 and Asp-231
with Ala led to a strong reduction of transport activity (Fig. 3). By
contrast, substitution of Asp-32 or Lys-135 with Ala maintains
signiﬁcant activity. Moreover, the Vmax value of the double mutant
D32A/K135A is much higher than those of K35A/D231A and E132A/
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indicate that the ion pairs Glu-132–Lys-234 and Lys-35–Asp-231
(Fig. 6) are important for function, whereas residues Asp-32 and Lys-
135 play a minor role. This conclusion parallels the observation that
the matrix gate of several mitochondrial carriers contains one or even
two weaker bonds than a salt bridge [3,10,30]. These weaker bonds
are represented by a hydrogen bond (e.g., dicarboxylate and FAD
carriers), a hydrophobic interaction (e.g., oxoglutarate and phosphate
carriers) and an aromatic-hydrogen interaction (e.g., FAD, pyrimidine
nucleotide and NAD+ carriers).
The experimental data reported herein are consistent with the
involvement of Arg-178, Asp-179 and Arg-275 in the binding of
carnitine to the CAC protein, as hypothesized for the corresponding
residues of the yeast CAC by bioinformatics [37]. Speciﬁcally, Asp-
179 would interact with the carnitine trimethylammonium group
whereas Arg-275 and Arg-178 with its carboxyl group. The Asp-179
and Arg-275 residues are fundamental for binding carnitine to CAC
(Fig. 7A and B) since their replacement with Ala causes a complete
loss of CAC activity. Furthermore, the electrical charge of the residues
at positions 179 and 275 is more crucial for carrier function than
side-chain length, since the substitution of either Asp with Glu at
position 179 or of Arg with Lys at position 275 affects the Vmax value
only slightly, as compared to that of the WT protein, whereas the Km
value is markedly increased. A positive charge at position 178 is also
important for CAC function. Thus, replacing Arg-178 with Lys does
not signiﬁcantly change the Km of carnitine for the carrier, whereas
substituting Arg at this position with the neutral amino acid Ala
causes a substantial increase in the Km. In addition, in both cases a
signiﬁcant decrease in Vmax occurs indicating that proper binding
inﬂuences the rate of catalysis. We also propose that in the absence
of transported substrate Arg-178 interacts with Asp-179 and this
interaction causes a distortion of the adjacent residues and is easily
broken by the oncoming substrate. This hypothesis is based on the
observation that the complete loss of D179A mutant activity is
partially rescued when a second mutation is introduced at positionFig. 7. View of the CAC residues which interact with carnitine. The residues and the carnitine
the residues involved in interactions with carnitine. The backbones are light gray, the side-ch
medium are gray; the side-chain of His-29 is depicted in medium gray except for the nitroge
(C) Top view, interaction of carnitine with H29, K35 and E132. The ionic interactions are indi
been represented using the molecular visualization program VMD. The position of carnitine
ArgusLab [41].178 leading to removal of the uncompensated positive charge, as in
R178A/D179A. It is worth mentioning that in this double mutant the
interaction of the carnitine trimethylammonium group with Asp-179
may be substituted, at least in part, by cation-π interactions [38,39]
with Phe-86, Tyr-186 and Phe-187, which line the carrier cavity in
the structural model of CAC.
The total binding energy of the interaction between the substrate
and the transporter triggers the conformational changes that lead to
the opening of the matrix gate and the closure of the cytosolic gate
[3,10]. Although some crude hypotheses have been advanced [3,40], it
is not yet known how the conformational changes occur and how the
matrix gate opens. Also unknown is whether the substrate partici-
pates in gate opening, as hypothesized in ref. [40] and, for explaining
the severe loss of activity caused by the R588Q mutation of the
aspartate-glutamate carrier isoform 2 which is responsible for a
disease named type II citrullinemia, in ref. [14]. The extremely low
activities of the mutants K35A and E132A as well as their high Km
values and very low catalytic efﬁciencies can be interpreted to
indicate that the carboxyl and trimethylammonium groups of
carnitine transiently interact with Lys-35 and Glu-132, respectively
(not necessarily simultaneously), breaking the salt bridges Lys-35–
Asp-231 and Glu-132–Lys-234 (Fig. 6). The importance of Asp-231
and Lys-234 in forming and breaking the matrix gate is in agreement
with the substantial decrease in the Vmax values and catalytic
efﬁciencies exhibited by the single mutants D231A and K234A.
Moreover, it may be that the temporary interaction of carnitine
with Lys-35 and/or Glu-132 is favored by the formation of a hydrogen
bond between the carnitine hydroxyl group and His-29 (Fig. 7C)
which contributes to the correct orientation of the substrate [23].
Among the charged residues predicted to be involved in the
cytosolic salt-bridge network, the substitution of Lys-97 or Lys-194
with Ala is rather well tolerated. By contrast, replacement of E191 or
E288with Ala affects Vmax, indicating that these residuesmay play an
important role in substrate transport. In light of the present results,
the binding energy resulting from the interaction among the residuesmolecule (in B and C) are depicted in a ball and stick representation. (A) Lateral view of
ains of the basic amino acids are dark gray and the side-chains of the acidic amino acids
n atoms which are dark gray. (B) Top view, interaction of carnitine with D179 and R275.
cated by dotted lines and the hydrogen bond by a dashed line. The homology model has
and the interactions with the protein residues have been optimized using the software
845N. Giangregorio et al. / Biochimica et Biophysica Acta 1797 (2010) 839–845involved in the cytosolic salt-bridge network of CAC is predicted to be
lower than that of other mitochondrial transporters. This would
facilitate the conformational transition of the carrier from the m-state
to the c-state in the absence of substrate, allowing CAC to catalyze the
uniport mode of transport from the cytosol to the mitochondrial
matrix [3,10] besides antiport, as previously demonstrated [12].
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